SPOP突变准前列腺癌中的STING1信号,并对PARP抑制剂诱导的增长抑制产生治疗脆弱性
Chuandong Geng1, Man-Chao Zhang1, Ganiraju C Manyam2
1Department of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
概括
前列腺癌中的斑点型POZ蛋白 (SPOP) 突变改变了STING信号,造成了脆弱性. PARP 抑制剂可以将这种信号转移到抗瘤反应中,从而改善治疗结果.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 免疫学 免疫学 免疫学
背景情况:
- 斑点型POZ蛋白 (SPOP) 在DNA损伤反应和基因组稳定性中起作用.
- 在SPOP中体质异构错义突变在前列腺癌 (PCa) 中普遍存在.
- SPOP突变与治疗反应有关,但患者的结果仍然异质,SPOP突变性割抗性前列腺癌 (CRPC) 的选择有限.
研究的目的:
- 阐明SPOP突变,STING信号传递和PARP抑制剂 (PARPi) 在前列腺癌中的有效性之间的机制联系.
- 确定针对SPOP突变CRPC的新型治疗策略.
主要方法:
- 在基因组和转录基因组瘤数据的in silico分析.
- 蛋白质组学分析.
- 转基因细胞系模型和临床前CRPC模型 (体外和体内).
主要成果:
- SPOP突变与治疗耐火CRPC的一个子集中的非正规 (NC) STING特征相关.
- 通常情况下,SPOP会破坏STING1的稳定性;SPOP突变会导致NC-STING-NF-κB信号的上调,通过瘤微环境促进瘤的生长.
- 在SPOP突变CRPC中,PARPi治疗将免疫抑制的NC-STING信号逆转为抗瘤规范的cGAS-STING-IFNβ信号,抑制瘤生长.
结论:
- 在前列腺癌中,SPOP关键调节了免疫抑制和抗瘤信号之间的平衡,这是DNA损伤诱导的STING1激活的下游信号.
- PARPi治疗是一种新的,基于生物标志物的策略,可以将STING信号重定向到SPOP突变CRPC中的抗瘤反应.
相关概念视频
Targeted Cancer Therapies
7.7K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.7K
Abnormal Proliferation
4.6K
Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.6K
The JAK-STAT Signaling Pathway
9.0K
Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as SH2...
9.0K
Treatment Resistant Cancers
3.3K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.3K
mTOR Signaling and Cancer Progression
3.8K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
3.8K
Interactions Between Signaling Pathways
6.3K
Signaling cascades usually lack linearity. Multiple pathways interact and regulate one another, allowing cells to integrate and respond to diverse environmental stimuli.
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
6.3K


